BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 5, 2018
View Archived Issues
Phase IIb trial of Mtb72F-AS02A vaccine shows 54% protection against active pulmonary tuberculosis
Read More
Let sleeping cells lie: Neutrophil extracellular traps untrap dormant tumor cells
Read More
C1QBP found to predict survival in mesothelioma patients under chemotherapy
Read More
Immunologically humanized mouse model better captures immune responses during hepatitis B infection
Read More
Phase II results presented for ustekinumab in patients with active systemic lupus erythematosus
Read More
PFKFB3 inhibitor selectively radiosensitizes cancer cells, blocking homologous recombination
Read More
Fluorescent virus-guided cytology detects active cancer cells in peritoneally disseminated GC
Read More
Nimbus Lakshmi patents TYK2 inhibitors
Read More
In situ TLR9-agonist vaccine plus low dose radiation induces systemic responses in indolent lymphoma
Read More
Takeda Pharmaceutical divulges new orexin OX2 receptor agonists
Read More
Janssen identifies new BACE inhibitors
Read More
Acquired resistance to enasidenib is mediated by a second-site mutation in the IDH2 dimer-interface
Read More
U.S. researchers divulge MALT1 inhibitors
Read More
Celyad enters agreement to use Horizon Discovery's shRNA technology
Read More
New triple-combination study explores plinabulin, nivolumab and ipilimumab in SCLC
Read More
Celgene opens recruitment in phase III study of JCAR-017 for second-line NHL
Read More
First patient enrolled in phase III study of glepaglutide for short bowel syndrome
Read More
Novartis initiates first-in-human study of CPK-850 for retinitis pigmentosa
Read More
Phase II data presented from NADIM study of neoadjuvant chemotherapy and immunotherapy in NSCLC
Read More
FDA approves Hemlibra for prophylaxis in hemophilia A without factor VIII inhibitors
Read More
Alnylam reports phase I/II data on lumasiran in PH1, initiates phase III trial
Read More
NIH research grant to support phase II program with PTI-125 in Alzheimer's
Read More
Oncology Venture cleared to include prostate cancer patients in phase II study of LiPlaCis
Read More
Oramed initiates pilot study of ORMD-0801 in NASH
Read More